

Fiscal Year 2011 Annual Review of Brovana™ (arformoterol tartrate)


Approval Criteria:

- Member must be age 18 or older
- Diagnosis of COPD, chronic bronchitis, or emphysema
- Prior trial with Advair®, Serevent®, or Foradil® within the past 45 days
- Clinical exception for members who are unable to effectively use hand-actuated devices or are stable on nebulized therapy.
- Quantity limit of 120 ml for a 30 day supply also applies.

Utilization Trend and Details

Fiscal Year	Members	Claims	Cost	Cost/Claim	Perdiem	Units	Days
2010	6	12	\$4,141.14	\$345.10	\$9.20	1,380	450
2011	11	41	\$15,416.77	\$376.02	\$11.05	4,860	1,395
Percent Change	83.30%	241.70%	272.30%	9.00%	20.10%	252.20%	210.00%
Change	5	29	\$11,275.63	\$30.92	\$1.85	3,480	945

Demographics of Members Utilizing Brovana™



Prior Authorization of Brovana™

Approved	14
Denied	3
Incomplete	11
Total	28

Prescribers of Brovana™

Specialty	Claims	Cost
Prescriber Only	18	\$6,885.95
Allergist	14	\$5,323.61
Internist	5	\$1,888.07
Family Practitioner	2	\$748.68
General Pediatrician	1	\$374.84
Cardiologist	1	\$195.62

Recommendations

The College of Pharmacy recommends no changes at this time.